Founded
Address
Clarus Ventures LLC
One Memorial Drive
Suite 1230
Cambridge, MA 02142
United States
Phone
Website
Recent investment activity
KANDO id: 30972
Company type
Life sciences venture capital firmRelation
Renamed to
Funds managed
Fund | Type | Vintage | Currency | Committed capital | IRR | x |
---|---|---|---|---|---|---|
Clarus IV-A LP | Venture | 2017 | USD | 789,700,000 | ||
Clarus IV-B LP | Venture | 2017 | USD | 789,700,000 | ||
Clarus IV-C LP | Venture | 2017 | USD | 789,700,000 | ||
Clarus IV-D LP | Venture | 2017 | USD | 789,700,000 | ||
Clarus DE II LP | Venture | 2014 | USD | 40,000,000 | ||
Clarus Defined Exit I LP | Venture | 2014 | USD | 100,000,000 | ||
Clarus Lifesciences III LP | Venture | 2014 | ||||
Clarus Ventures III GP LP | Venture | 2014 | ||||
Clarus Lifesciences II LP | Venture | 2008 | USD | 14.80 % | 1.80 x | |
Clarus Lifesciences I LP | Venture | 2006 | USD | 3.90 % | 1.20 x | |
Clarus Ventures II | Venture | USD | 697,000,000 |
Funding rounds
Investor | Profile | Country | Notes | |
---|---|---|---|---|
The Blackstone Group LP | Private equity firm | Led the round. |
Investment preferences
Top investment portfolio themes
pharmaceuticals (1)
Investment activity status
Not investing
Selected investments
Displaying 1 - 25 of 38Company | Profile | Country | Date Sort ascending | Funding | ||
---|---|---|---|---|---|---|
Oxford Immunotec Ltd | Venture | |||||
Flowonix Medical | A medical device company dedicated to helping those who suffer from chronic disorders. | N/A | ||||
Catabasis Pharmaceuticals Inc | Series A | |||||
NanoString Technologies Inc | A life sciences company, markets solutions for detecting and counting large sets of target molecules in biological samples for researchers. | Series D | ||||
Cleave Biosciences Inc | Drug development company focused on novel targets in cellular protein homeostasis pathways | Series A | ||||
SARcode Bioscience Inc | Series B | |||||
Aerie Pharmaceuticals Inc | Series B | |||||
TyRx Inc | N/A | |||||
Oxford Immunotec Ltd | Series D | |||||
Catabasis Pharmaceuticals Inc | Series A | |||||
Pearl Therapeutics Inc | Developing unique dual and triple combination products for the treatment of widely prevalent respiratory diseases | N/A | ||||
Zogenix Inc | A pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. | Series B Follow-on investment | ||||
NanoString Technologies Inc | A life sciences company, markets solutions for detecting and counting large sets of target molecules in biological samples for researchers. | Series C | ||||
Aerovance Inc | N/A | |||||
Lycera Corp | Series A | |||||
Heptares Therapeutics Ltd | Series A | |||||
Virdante Pharmaceuticals Inc | A privately held biopharmaceutical company focused on the development and commercialization of drugs for autoimmune and inflammatory disorders. | Series A | ||||
Biolex Therapeutics Inc | Series D | |||||
Link Medicine Inc | Advancing disease-modifying technologies targeted at Alzheimer's, Parkinson's and other neurodegenerative diseases | Series C | ||||
Achillion Pharmaceuticals Inc | Biopharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. | N/A | ||||
ESBATech AG | Switzerland based Biomedical Research Unit of Alcon | Series B Initial investment | ||||
Avanir Pharmaceuticals Inc | A biopharmaceutical company focused on bringing innovative medicines to patients with central nervous system disorders of high unmet medical need. | N/A | ||||
TyRx Inc | N/A | |||||
Zogenix Inc | A pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. | N/A Initial investment | ||||
Oxford Immunotec Ltd | Series C led the round |